Middle East and Africa Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)
The Middle East & Africa monoclonal antibodies market is expected to reach US$ 5,741.1 million by 2028 from US$ 3,198.9 million in 2021. The market is estimated to grow at a CAGR of 8.7% from 2021–2028.
The high focus of pharmaceutical giants on developing novel monoclonal antibodies resulted in significant research collaborations that can pave the way to key market share in the coming years. New manufacturers seek strategic collaborations to increase uptake of such novel techniques, as they intend to enter a highly competitive market to sustain their position. For records, in October 2017, Incyte and MacroGenics, Inc. announced a partnership and license agreement for "MGA012", an investigational monoclonal antibody of MacroGenics, Inc. Such factors are projected to support the Middle East & Africa market growth in the coming years. Furthermore, strategic research collaborations also play a vital role in detecting pharmacological actions of mABs soon after the diagnosis.The demand for monoclonal antibody-based products in Saudi Arabia have a high success rate in clinical development and is reported that the probability of FDA approvals for mABs in Phase 1 of development in ~14.1% that is almost twice the approval rate of small molecule drugs (~7.6%). On the other hand, the IAVI report states that with the onset of pandemic worldwide many biopharmaceutical companies sell mABs based products at affordable prices. For example, in South Africa, Roche sells its breast cancer mAB "trastuzumab" as both Herceptin the original brand as a second brand called "Hercelon". Apart from that, as availability of these mABs is limited, various pharmaceutical companies are conducting clinical trials in middle-income counties. For example, Merck is conducting clinical trials in several middle-income countries such as South Africa, Colombia, and Malaysia. Such aforementioned factors have positive influence in the regional market thereby witnessing high adoption of monoclonal antibody in Middle East and Africa region amid COVID-19 pandemic.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The Middle East & Africa monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.
Middle East & Africa Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report :
Middle East & Africa Monoclonal Antibodies Market Segmentation
By Source
- Human
- Humanized
- Chimeric
- Murine
By Production Method
- In-Vitro
- In-Vivo
By Indication
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Inflammatory Diseases
- Microbial Diseases
- Others
By Application
- Therapeutic Applications
- Diagnostic Applications
- Research Applications
By End-User
- Hospitals
- Research Institutes
- Others
By Country
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Companies Mentioned
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc.
- Amgen Inc
- DAIICHI SANKYO COMPANY, LIMITED
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Source
1.3.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Production Method
1.3.3 Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Indication
1.3.4 Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Application
1.3.5 Middle East & Africa Monoclonal Antibodies (mAbs) Market – By End-User
1.3.6 Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Monoclonal Antibodies (mAbs) Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Middle East & Africa PEST Analysis
4.3 Experts Opinion
5. Monoclonal Antibodies (mAbs) Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Cancer and Other Chronic Diseases
5.1.2 mABs Uptake Proves to be Effective During Pandemic Outbreak
5.2 Market Restraints
5.2.1 Low Awareness, Accessibility, and High Cost
5.3 Market Opportunities
5.3.1 Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity
5.4 Future Trends
5.4.1 Strategic Research Collaborations
5.5 Impact Analysis
6. Monoclonal Antibodies (mAbs) Market– Middle East & Africa Analysis
6.1 Middle East & Africa Monoclonal Antibodies (mAbs) Market, By Geography - Forecast and Analysis
7. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028– by Source
7.1 Overview
7.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market, By Source, 2020 & 2028 (%)
7.3 Murine
7.3.1 Overview
7.3.2 Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Chimeric
7.4.1 Overview
7.4.2 Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.5 Humanized
7.5.1 Overview
7.5.2 Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.6 Human
7.6.1 Overview
7.6.2 Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
8. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Production Method
8.1 Overview
8.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)
8.3 In-Vivo
8.3.1 Overview
8.3.2 In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
8.4 In-Vitro
8.4.1 Overview
8.4.2 In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Indication
9.1 Overview
9.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)
9.3 Cancer
9.3.1 Overview
9.3.2 Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.5 Inflammatory Diseases
9.5.1 Overview
9.5.2 Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.6 Infectious Diseases
9.6.1 Overview
9.6.2 Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.7 Microbial Diseases
9.7.1 Overview
9.7.2 Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Application
10.1 Overview
10.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)
10.3 Diagnostic Applications
10.3.1 Overview
10.3.2 Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.4 Therapeutic Applications
10.4.1 Overview
10.4.2 Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.5 Research Applications
10.5.1 Overview
10.5.2 Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – End-User
11.1 Overview
11.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)
11.3 Hospitals
11.3.1 Overview
11.3.2 Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.4 Research Institutes
11.4.1 Overview
11.4.2 Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.5 Others
11.5.1 Overview
11.5.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
12. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 – Geographical Analysis
12.1 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028
12.1.1 Overview
12.1.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.1.3 Middle East & Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.1.4 Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)
12.1.5 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
12.1.6 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.1.7 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
12.1.8 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
12.1.8.1 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.1.8.1.1 Overview
12.1.8.1.2 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.1.8.1.3 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.1.8.1.4 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
12.1.8.1.5 UAE: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
12.1.8.1.6 UAE: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.1.8.1.7 UAE: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
12.1.8.2 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.1.8.2.1 Overview
12.1.8.2.2 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.1.8.2.3 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.1.8.2.4 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
12.1.8.2.5 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
12.1.8.2.6 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.1.8.2.7 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
12.1.8.3 South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.1.8.3.1 Overview
12.1.8.3.2 South Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.1.8.3.3 South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.1.8.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Production (US$ Million)
12.1.8.3.5 South Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
12.1.8.3.6 South Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
12.1.8.3.7 South Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
13. Impact Of COVID-19 Pandemic on Monoclonal Antibodies (mAbs) Market
13.1 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
14. Monoclonal Antibodies (mAbs) Market–Industry Landscape
14.1 Overview
14.2 Growth Strategies Done by the Companies in the Market, (%)
14.3 Organic Developments
14.3.1 Overview
14.4 Inorganic Developments
14.4.1 Overview
15. Company Profiles
15.1 Novartis AG
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc.
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 GlaxoSmithKline plc.
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Amgen Inc.
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 DAIICHI SANKYO COMPANY LIMITED
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 F. HOFFMANN-LA ROCHE LTD.
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 AstraZeneca
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Bayer AG
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Bristol-Myers Squibb Company
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
16. Appendix
16.1 About The Insight Partners
16.2 Glossary of Terms
LIST OF TABLES
Table 1. Middle East & Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 2. Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 3. Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 4. Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 5. Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 6. UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 7. UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 8. UAE: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 9. UAE: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 10. UAE: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 11. Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 12. Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 13. Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 14. Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 15. Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 16. South Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 17. South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 18. South Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 19. South Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 20. South Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 21. Organic Developments Done by Companies
Table 22. Inorganic Developments Done by Companies
Table 23. Glossary of Terms
LIST OF FIGURES
Figure 1. Monoclonal Antibodies (mAbs) Market Segmentation
Figure 2. Middle East & Africa Monoclonal Antibodies (mAbs) Market Overview
Figure 3. Human Segment Held Largest Share of Source Segment in Monoclonal Antibodies (mAbs) Market
Figure 4. South Africa is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Middle East & Africa Monoclonal Antibodies (mAbs) Market, Industry Landscape
Figure 6. Middle East & Africa: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis of Drivers and Restraints Pertaining to Monoclonal Antibodies (mAbs) Market
Figure 9. Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Geography Forecast and Analysis – 2021 - 2028
Figure 10. Middle East & Africa Monoclonal Antibodies (mAbs) Market, by Source, 2020 & 2028 (%)
Figure 11. Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 15. Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)
Figure 16. In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 18. Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)
Figure 19. Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 22. Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 23. Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)
Figure 26. Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 27. Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 28. Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 29. Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)
Figure 30. Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 32. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 33. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 34. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 35. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
Figure 36. UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. Impact of COVID-19 Pandemic in Middle East & Africa Country Markets
Figure 40. Growth Strategies Done by the Companies in the Market, (%)
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc.
- Amgen Inc
- DAIICHI SANKYO COMPANY, LIMITED
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa monoclonal antibodies market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.